Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2017 - Issue 0 supplementary

Treatment of Pigment Epithelial Detachment Using Bevacizumab Download PDF


Ghader Motarjemizadeh1, Jafar Jafapour2, Naser Samadi Aidenloo3, Jafar Nasiri4, Rohollah Valizadeh5
Abstract

Background: Pigment epithelial detachment (PED) is a pathological process in which the retinal pigment epithelium separates from its underlying membrane (Bruch). Although the PED can be spread in macular disorders, coherence of disorder with degenerative age-related macular neovascularization is impressive and can be marker of disease, disease progression and in some cases the indicator as resistance to treatment. Objective: The aim of this study was to evaluate the effect of bevacizumab in the treatment of pigment epithelial detachment. Methods: In this retrospective study the data of patients with detachment of pigment epithelial were studied who referred to eye clinic in Imam Khomeini hospital of Urmia, Iran and treated by bevacizumab. Variables of study included age, sex, height of PED before injection of bevacizumab and 1, 3, 6 and 12 months after injection of bevacizumab. Under sterile Conditions and after prepping and draping and setting speculum in aphakic and pseudophakic patients, injection from distance of 3.5mm of limbus and in phakic patients from distance of 4mm of limbus administrated with dosage of 1.25 mg bevacizumab.5 days after surgery, eye drop betamethasone every 4hours and tablet of ciprofloxacin 500 mg every 12 hours were administered. Results: In this retrospective study, 30 patients with pigment epithelium detachment who have been treated by bevacizumab were studied. Age range was from 58 to 79 years and the average age of the patients was 70.16±5.99 years. In this study 16 patients were female (53.3%) and 14 patients were male (46.7%).The average height of PED before injection was compared to the average height of PED 1, 3, 4 and 12 months after injection and it was significantly different (P=0.001) Conclusion: Bevacizumab can be an appropriate treatment for patients with pigment epithelium detachment. Funding: This research has been financially supported by Research Council of Mashhad University of Medical Sciences.
QR code:

Short Link:
Quick Access

Pharmacophore
ISSN: 2229-5402

Copyright © 2024 Pharmacophore
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.